NDRA vs. HSDT, TIVC, NUWE, GMVDF, VRPX, BPTSY, AGRX, ZCMD, PHIO, and ALBT
Should you be buying ENDRA Life Sciences stock or one of its competitors? The main competitors of ENDRA Life Sciences include Helius Medical Technologies (HSDT), Tivic Health Systems (TIVC), Nuwellis (NUWE), G Medical Innovations (GMVDF), Virpax Pharmaceuticals (VRPX), Biophytis (BPTSY), Agile Therapeutics (AGRX), Zhongchao (ZCMD), Phio Pharmaceuticals (PHIO), and Avalon GloboCare (ALBT). These companies are all part of the "medical" sector.
Helius Medical Technologies (NASDAQ:HSDT) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, community ranking, risk, profitability, dividends, media sentiment and valuation.
Helius Medical Technologies has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.
ENDRA Life Sciences received 215 more outperform votes than Helius Medical Technologies when rated by MarketBeat users. Likewise, 62.67% of users gave ENDRA Life Sciences an outperform vote while only 57.14% of users gave Helius Medical Technologies an outperform vote.
Helius Medical Technologies has higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Helius Medical Technologies, indicating that it is currently the more affordable of the two stocks.
18.6% of Helius Medical Technologies shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 7.3% of Helius Medical Technologies shares are owned by insiders. Comparatively, 4.8% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Helius Medical Technologies and Helius Medical Technologies both had 5 articles in the media. ENDRA Life Sciences' average media sentiment score of 0.53 beat Helius Medical Technologies' score of 0.21 indicating that Helius Medical Technologies is being referred to more favorably in the media.
ENDRA Life Sciences has a net margin of 0.00% compared to ENDRA Life Sciences' net margin of -1,374.22%. Helius Medical Technologies' return on equity of -197.36% beat ENDRA Life Sciences' return on equity.
Helius Medical Technologies currently has a consensus price target of $54.50, indicating a potential upside of 2,927.78%. Given ENDRA Life Sciences' higher probable upside, equities research analysts clearly believe Helius Medical Technologies is more favorable than ENDRA Life Sciences.
Summary
Helius Medical Technologies beats ENDRA Life Sciences on 10 of the 15 factors compared between the two stocks.
Get ENDRA Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for NDRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NDRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ENDRA Life Sciences Competitors List
Related Companies and Tools
